The aim of this study was to investigate the accuracy of single-time-point (STP) renal
dosimetry imaging using SPECT/CT data, a nonlinear mixed-effects (NLME) model, and a …

1405 Introduction: Treatment planning of Lu-177-labelled PSMA (Lu-177-PSMA) therapy
using a physiologically-based pharmacokinetic (PBPK) model requires knowledge of its …

Purpose For prostate-specific membrane antigen-directed radioligand therapy (PSMA-
RLT),[177 Lu] Lu-PSMA-617 and [177 Lu] Lu-PSMA-I&T are the currently preferred …

The radiation dose to the kidneys should be monitored in prostate cancer patients treated
with radioligand therapy (RLT) targeting the prostate-specific membrane antigen (PSMA) …

Radiopharmaceutical therapies (RPTs) with 177Lu-prostate-specific membrane antigen
(PSMA) ligands have demonstrated promising results for the treatment of metastatic …

Purpose The knowledge of the contribution of anatomical and physiological parameters to
interindividual pharmacokinetic differences could potentially be used to improve …

Abstract Background Dosimetry in [177Lu] Lu-PSMA therapy is a valuable tool to assess
treatment efficacy and toxicity. This study aims to develop a clinically implementable protocol …

Background 177Lu-PSMA therapy has been successfully used to prolong the survival of
patients with metastatic castration-resistant prostate cancer. Patient-specific dosimetry …

Background Individualized dosimetry is recommended for [177 Lu] Lu-PSMA radioligand
therapy (RLT) which is resource-intensive and protocols are often not optimized. Therefore …

Background Personalized dosimetry for Lu-177-PSMA treatment requires multiple-time-point
SPECT/CT scans to calculate time-integrated activity (TIA). This study evaluates two-time …